The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Harvard University · Beth Israel Deaconess Medical Center
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
573
total citations
- FWCI
- 29.73
- Percentile
- 100%
- References
- 98
Citations per year
Authors
3Topics & keywords
Topics
Keywords
- Nivolumab
- Medicine
- Pembrolizumab
- Ipilimumab
- Dacarbazine
- Melanoma
- Oncology
- Immune checkpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.